Soligenix, Inc. Common Stock
SNGXSoligenix, Inc. is a biotechnology company focused on developing and commercializing innovative products in the areas of infectious disease, oncology, and gastrointestinal disorders. The company leverages its proprietary ThermoVax vaccine thermosensitive platform and other advanced technologies to develop therapies and vaccines, aiming to address unmet medical needs through research and development efforts.
Company News
Soligenix reported a net loss of $2.5 million in Q3 2025, with ongoing clinical trials for HyBryteâ„¢ in cutaneous T-cell lymphoma and continued development of rare disease treatments. The company maintains approximately $10.5 million in cash and is focused on strategic milestones through 2026.
Multiple healthcare stocks experienced significant pre-market price movements, with some companies seeing notable gains while others faced declines.
Soligenix, a late-stage biopharmaceutical company, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, with an on-demand presentation available on September 5th.
Pharmaceutical companies are advancing treatments for rare diseases, with Soligenix leading efforts in developing HyBryte, a promising therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting older adults.
The non-Hodgkin's lymphoma market is expected to grow significantly between 2025-2034, driven by increasing incidence, advancements in targeted therapies, emerging treatments, and improved early detection efforts.
